-
2023-504541-31-00
5
2024-03-06
Myelodysplastic syndrome
-
2023-503428-24-00
4
2024-01-19
Neoplasms, Head and Neck
-
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
-
2023-504413-80-00
5
2023-12-07
Obesity
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2024-513721-23-00
4
2022-12-15
ADVANCED TRIPLE NEGATIVE BREAST CANCER
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-509345-12-00
5
2022-06-22
Multiple Sclerosis
-
2024-510800-35-00
5
2022-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-511901-52-00
4
2022-03-24
Adult patients affected by recurrent/metastatic, platinum resistant na
-
2024-511633-35-00
4
2022-03-21
Mantle cell lymphoma
-
2024-518304-53-00
5
2022-02-02
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-511599-33-00
5
2021-12-22
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2024-511636-27-00
5
2021-12-01
Follicular Lymphoma
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2023-507698-16-00
5
2021-10-14
Chronic Lymphocytic Leukemia/Small
Lymphocytic Lymphoma (BRUIN CLL-322
-
2024-514122-23-00
4
2021-10-07
Marginal Zone Lymphomas refractory to or in first or greater relapse a
-
2023-508968-30-00
5
2021-09-08
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2024-516868-28-00
4
2021-05-04
Ph+ Acute Lymphoblastic Leukemia